Table 2.
Systemic treatment modalities given to the 183 patients with ALK+ advanced NSCLCs before brigatinib.
| Treatment History | n (%) |
|---|---|
| Previous lines received, n | |
| 1 | 15 (8.2) |
| 2 | 47 (25.7) |
| 3 | 74 (40.4) |
| 4 | 26 (14.2) |
| >5 | 22 (12) |
| First-line modality (n = 183) | |
| Chemotherapy | 100 (54.6) |
| Crizotinib | 78 (42.6) |
| Alectinib | 5 (2.7) |
| Second-line modality (n = 169) | 169 (92.3) |
| Chemotherapy | 25 (13.7) |
| Crizotinib, | 83 (45.3) |
| Ceritinib | 55 (30.1) |
| Alectinib | 5 (2.7) |
| Immunotherapy | 1 (0.5) |
| Third-line modality (n = 122) | 122 (72.6) |
| Chemotherapy | 25 (20.5) |
| Crizotinib | 10 (8.2) |
| Ceritinib | 76 (62.3) |
| Alectinib | 4 (3.3) |
| Agent received just before brigatinib | 183 (100) |
| Chemotherapy | 27 (14.7) |
| Crizotinib | 27 (14.7) |
| Ceritinib | 114 (61.6) |
| Alectinib | 9 (4.9) |
| Lorlatinib | 6 (3.3) |
| Immunotherapy | 1 (1.1) |
| Number progressing before brigatinib | 179 |
| 1 | 34 (18.6) |
| 2 | 49 (26.8) |
| 3 | 60 (32.8) |
| 4 | 21 (11.5) |
| >5 | 15 (8.2) |